Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection

Cancer Research

Volumn 58, Issue 12, 1998, Pages 2509-2514

  Schreurs, Marco W J ^a   De Boer, Annemiek J ^a   Figdor, Carl G ^a   Adema, Gosse J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; GLYCOPROTEIN; IMMUNOGLOBULIN G; PLASMID DNA;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; INTRADERMAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; MELANOCYTE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY; VACCINATION;

ANIMALS; ANTIBODY FORMATION; ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY; MALE; MELANOCYTES; MELANOMA, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; NEOPLASM PROTEINS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION;

EID: 0032526176     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Van den Eynde, B. J., and van der Bruggen, P. T cell defined tumor antigens. Curr. Opin. Immunol., 9: 684-693, 1997.
2. Kawakami, Y., and Rosenberg, S. A. Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immunogene therapy. Int. Rev. Immunol., 14: 173-192, 1997.
3. Anichini, A., Maccalli, C., Mortarini, R., Salvi, S., Mazzocchi, A., Squarcina, P., Herlyn, M., and Parmiani, G. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients. J. Exp. Med., 177: 989-998, 1993.
4. Bakker, A. B. H., Schreurs, M. W. J., Deboer, A. J., Kawakami, Y., Rosenberg, S. A., Adema, G. J., and Figdor, C. G. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. Exp. Med., 179: 1005-1009, 1994.
5. Bakker, A. B. H., Marland, G., De Boer, A. J., Huijbens, R. J., Danen, E. H., Adema, G. J., and Figdor, C. G. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res., 55: 5330-5334, 1995.
6. Boon, T., Coulie, P., Marchand, M., Weynants, P., Wolfel, T., and Brichard, V. Genes coding for tumor rejection antigens: perspectives for specific immunotherapy. Important Adv. Oncol., 53-69, 1994.
7. Rosenberg, S. A., Kawakami, Y., Robbins, P. F., and Wang, R. F. Identification of the genes encoding cancer antigens: implications for cancer immunotherapy. Adv. Cancer Res., 70: 145-177, 1996.
8. Yee, C., Riddell, S. R., and Greenberg, P. D. Prospects for adoptive T cell therapy. Curr. Opin. Immunol., 9: 702-708, 1997.
9. Chen, L., Ashe, S., Brady, W. A., Hellstrom, I., Hellstrom, K. E., Ledbetter, J. A., McGowan, P., and Linsley, P. S. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell, 71: 1093-1102, 1992.
10. Mandelboim, O., Vadai, E., Fridkin, M., Katz Hillel, A., Feldman, M., Berke, G., and Eisenbach, L. Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides. Nat. Med., 1: 1179-1183, 1995.
11. Mayordomo, J. I., Zorina, T., Storkus, W. J., Zitvogel, L., Celluzzi, C., Falo, L. D., Melief, C. J., Ildstad, S. T., Kast, W. M., Deleo, A. B., and Lotze, M. T. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med., 1: 1297-1302, 1995.
12. Zhai, Y., Yang, J. C. Kawakami, Y., Spiess, P., Wadsworth, S. C., Cardoza, L. M., Couture, L. A., Smith, A. E., and Rosenberg, S. A. Antigen-specific tumor vaccines: development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. J. Immunol., 156: 700-710, 1996.
13. Syrengelas, A. D., Chen, T. T., and Levy, R. DNA immunization induces protective immunity against B-cell lymphoma. Nat. Med., 2: 1038-1041, 1996.
14. Donnelly, J. J., Ulmer, J. B., Shiver, J. W., and Liu, M. A. DNA vaccines. Annu. Rev. Immunol., 15: 617-648, 1997.
15. Tighe, H., Corr, M., Roman, M., and Raz, E. Gene vaccination: plasmid DNA is more than just a blueprint. Immunol. Today, 19: 89-87, 1998.
16. Fidler, I. J. Selection of successive tumor lines for metastasis. Nature (Lond.), 242: 148-149, 1973.
17. Lin, A. Y., Devaux, B., Green, A., Sagerstrom, C., Elliott, J. F., and Davis, M. M. Expression of T cell antigen receptor heterodimers in a lipid-linked form. Science (Washington DC), 249: 677-679, 1990.
18. Graham, F. L., and Eb, A. J. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology, 52: 456-467, 1973.
19. Baker, S. J., Markowitz, S., Fearon, E. R., Willson, J. K., and Vogelstein, B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science (Washington DC), 249: 912-915, 1990.
20. Kawakami, Y., Zakut, R., Topalian, S. L., Stotter, H., and Rosenberg, S. A. Shared human melanoma antigens: recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas. J. Immunol., 148: 638-643, 1992.
21. Adema, G. J., De Boer, A. J., van't Hullenaar, R., Denijn, M., Ruiter, D. J., Vogel, A. M., and Figdor, C. G. Melanocyte lineage-specific antigens recognized by monoclonal antibodies NKI-beteb, HMB-50, and HMB-45 are encoded by a single cDNA. Am. J. Pathol., 143: 1579-1585, 1993.
22. Colombo, M. P., and Forni, G. Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol. Today, 15: 48-51, 1994.
23. Schreurs, M. W. J., De Boer, A. J., Schmidt, A., Figdor, C. G., and Adema, G. J. Cloning, expression and tissue distribution of the murine homologue of the melanocyte lineage-specific antigen gp100. Melanoma Res., 7: 463-470, 1997.
24. Casares, S., Inaba, K., Brumeanu, T. D., Steinman, R. M., and Bona, C. A. Antigen presentation by dendritic cells after immunization with DNA encoding a major histocompatibility complex class II-restricted viral epitope. J. Exp. Med., 186: 1481-1486, 1997.
25. Roman, M., Martin Orozco, E., Goodman, J. S., Nguyen, M. D., Sato, Y., Ronaghy, A., Kornbluth, R. S., Richman, D. D., Carson, D. A., and Raz, E. Immunostimulalory DNA sequences function as T helper-1-promoting adjuvants. Nat. Med., 3: 849-854, 1997.
26. Hara, I., Takechi, Y., and Houghton, A. N. Implicating a role for immune recognition of sell in tumor rejection: passive immunization against the brown locus protein. J. Exp. Med., 182: 1609-1614, 1995.
27. Zhai, Y., Yang, J. C., Spiess, P., Nishimura, M. I., Overwijk, W. W., Roberts, B., Restifo, N. P., and Rosenberg, S. A. Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. J. Immunother., 20: 15-25, 1997.